T. Rowe Price Associates
OCDX

T. Rowe Price Associates’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

T. Rowe Price Associates’s Portfolio OCDX Stock Details OCDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,489,153
Closed -$364M – 3036
2022
Q1 		$364M Sell
19,489,153
-492,505
-2% -$8.86M 0.04% 393
2021
Q4 		$427M Buy
19,981,658
+115,758
+0.6% +$2.28M 0.04% 374
2021
Q3 		$367M Buy
19,865,900
+4,069,037
+26% +$81.9M 0.03% 400
2021
Q2 		$338M Sell
15,796,863
-74,725
-0.5% -$1.52M 0.03% 428
2021
Q1 		$306M Buy
+15,871,588
New +$280M 0.03% 437

Other funds holding OCDX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's OCDX Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 19,489,153 shares — an estimated $364M sold.

T. Rowe Price Associates first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $427M in Q4 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 19,489,153 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $364M.
  • T. Rowe Price Associates first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
  • T. Rowe Price Associates's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $427M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.